TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05091008

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ledipasvir-Sofosbuvir 90 Mg-400 Mg Oral Tablet
Description: proper history was taken. HCV genotyping was done revealed GT 4 in all included patients. Basic ECG and abdominal US were performed prior to treatment. Concomitant HBV infection was excluded by HBs Ag and anti-HBc antibody HIV screening was done prior to treatment. Basic investigations were done prior to therapy. All included patients received Ledipasvir-Sofosbuvir fixed-dose combination one tablet (90 mg Ledipasvir, 400 mg Sofosbuvir), orally once daily at a fixed time with or without food for 12 weeks. Regular visits were arranged at 4, 8, and 12 weeks with easy access to the pediatric hepatology unit and the treating physician if any urgent problem in between the visits. Every visit, laboratory investigations were checked. Adverse events (after excluding other possible causes) were reported for the safety profile of the drug. The efficacy of the drug, HCV-RNA was assessed by quantitative real-time PCR at 4 weeks and after the end of the treatment course (12 weeks)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ledipasvir-Sofosbuvir 90 Mg-400 Mg Oral Tablet
Description: proper history was taken. HCV genotyping was done revealed GT 4 in all included patients. Basic ECG and abdominal US were performed prior to treatment. Concomitant HBV infection was excluded by HBs Ag and anti-HBc antibody HIV screening was done prior to treatment. Basic investigations were done prior to therapy. All included patients received Ledipasvir-Sofosbuvir fixed-dose combination one tablet (90 mg Ledipasvir, 400 mg Sofosbuvir), orally once daily at a fixed time with or without food for 12 weeks. Regular visits were arranged at 4, 8, and 12 weeks with easy access to the pediatric hepatology unit and the treating physician if any urgent problem in between the visits. Every visit, laboratory investigations were checked. Adverse events (after excluding other possible causes) were reported for the safety profile of the drug. The efficacy of the drug, HCV-RNA was assessed by quantitative real-time PCR at 4 weeks and after the end of the treatment course (12 weeks)
Study: NCT02641379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: PEG-IFN is available as 180 microgram (mcg) per 0.5 mL, prefilled syringe and pen for single dose sc. injection\\n

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: PEG-IFN is available as 180 microgram (mcg) per 0.5 mL, prefilled syringe and pen for single dose sc. injection\\n

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: PEG-IFN is available as 180 microgram (mcg) per 0.5 mL, prefilled syringe and pen for single dose sc. injection\\n

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: PEG-IFN is available as 180 microgram (mcg) per 0.5 mL, prefilled syringe and pen for single dose sc. injection\\n

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin is available as 200 mg tablets
Study: NCT00623649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VCH 916
Description: Dose escalation study with a full review of all safety data following each cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VCH 916
Description: Dose escalation study with a full review of all safety data following each cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VCH 916
Description: Dose escalation study with a full review of all safety data following each cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VCH 916
Description: Dose escalation study with a full review of all safety data following each cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Dose escalation study with a full review of all safety data following each cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Dose escalation study with a full review of all safety data following each cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Dose escalation study with a full review of all safety data following each cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Dose escalation study with a full review of all safety data following each cohort.
Study: NCT04931498

Intervention type: OTHER
Intervention: Questionnaire
Description: Medical history, demographics and lifestyle factors will be assessed by the participant.

Intervention type: OTHER
Intervention: Questionnaire
Description: Medical history, demographics and lifestyle factors will be assessed by the participant.
Study: NCT02641379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin is available as 200 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin is available as 200 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin is available as 200 mg tablets
Study: NCT02017314

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Study: NCT04931498

Intervention type: OTHER
Intervention: Anthropometric measurements: height, weight, and body fat
Description: Height measured by stadiometer. Weight and body fat measured by Tanita scale bioelectrical impedance analysis.
Study: NCT02017314

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Study: NCT02723149

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Marijuana Approach Avoidance Training
Description: Approach Avoidance Training (AAT) is a novel computerized procedure that modifies implicit approach tendencies by training individuals to selectively avoid drug- related stimuli, thereby overriding habitual approach tendencies. Participants are randomized to either the treatment or sham condition. Treatment duration involves 6 training sessions of approximately 15 minutes each (400 trials). AAT requires minimal training and involves only a computer and a joystick, in which participants are either pulling or pushing the joystick when different marijuana or non-marijuana images are displayed with either yellow (pull) or blue (push) border.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Marijuana Approach Avoidance Training
Description: Approach Avoidance Training (AAT) is a novel computerized procedure that modifies implicit approach tendencies by training individuals to selectively avoid drug- related stimuli, thereby overriding habitual approach tendencies. Participants are randomized to either the treatment or sham condition. Treatment duration involves 6 training sessions of approximately 15 minutes each (400 trials). AAT requires minimal training and involves only a computer and a joystick, in which participants are either pulling or pushing the joystick when different marijuana or non-marijuana images are displayed with either yellow (pull) or blue (push) border.
Study: NCT00721786

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: UCSF/SFGH Internet Stop Smoking Study site
Description: Internet stop smoking site in Spanish and English
Study: NCT00256152

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AF Suppression Pacing Algorithm
Study: NCT01478126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N(2)-L-Alanine L-Glutamine dipeptide
Description: Intravenous infusion of glutamine in total dose of 2 g/kg/day (rate=2\*weight/24 ml/h). Infusion starts in operating room and ends next day after the surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous infusion of 0,9% solution of NaCl, rate=2\*weight/24. Infusion starts in operating room and ends next day after the surgery.
Study: NCT04552587

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heart APP
Description: The HEART intervention includes a care planning visit for patients and caregivers and an App for caregivers focused on nutrition, self-care and support.
Study: NCT01083212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1656
Description: Single dose,oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1656
Description: Single dose,oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Description: Oral tablet bid on day 1 - 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Description: Oral tablet bid on day 1 - 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral tablet bid on day 1-5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral tablet bid on day 1-5
Study: NCT00506155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avastin
Description: 10 mg/kg by vein over 90 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 70 mg/m\^2 by vein over 4 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 30 mg/m\^2 by vein over 15 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 30 mg/m\^2 by vein over 30 minutes
Study: NCT00506155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine Sulfate
Description: 3 mg/m\^2 by vein over 30 minutes
Study: NCT03072134

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Neural stem cells loaded with an oncolytic adenovirus
Description: The primary objectives are to evaluate the safety of the combined therapy and determine the maximum tolerated dose (MTD) for a future Phase II study.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Neural stem cells loaded with an oncolytic adenovirus
Description: The primary objectives are to evaluate the safety of the combined therapy and determine the maximum tolerated dose (MTD) for a future Phase II study.
Study: NCT01018199

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CRP
Description: C-reactive protein guided antibiotic therapy plasma CRP measurement to guide the duration of antibiotic therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PCT
Description: Procalcitonin guided antibiotic therapy plasma PCT measurement to guide the duration of antibiotic therapy
Study: NCT04174911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOL-DP-o-08
Description: BOL-DP-o-08 sublingual drops
Study: NCT04931498

Intervention type: OTHER
Intervention: Blood pressure and heart rate
Description: Parameters will be measured using a validated, automated device while seated and again after 3-5 min standing. All measurements will be done in triplicate.
Study: NCT04174911

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: sublingual drops
Study: NCT04931498

Intervention type: OTHER
Intervention: Blood pressure and heart rate
Description: Parameters will be measured using a validated, automated device while seated and again after 3-5 min standing. All measurements will be done in triplicate.

Intervention type: PROCEDURE
Intervention: Venepuncture (GMPR)
Description: A blood sample of approximately 50 ml of venous blood will be taken. From the obtained blood sample, measurements will include a full blood count and the following phenotyping tests:~* Flow cytometry to quantify cell surface expression of key erythroid markers~* Proteomic analysis of isolated erythrocytes using mass spectrometry

Intervention type: PROCEDURE
Intervention: Venepuncture (SWAP70)
Description: A blood sample of approximately 50 ml of venous blood will be taken. From the obtained blood sample, measurements will include a full blood count and the following phenotyping tests:~* Flow cytometry to quantify cell surface expression of key markers~* Fluorescence-Activated Cell Sorting (FACS) to assess B-cell receptor signalling and to isolate cell type-specific RNA for transcriptome analysis~* Immunoglobulin isotype titre analysis in plasma~* Isolation of monocytes for subsequent use in phagocytosis assays
Study: NCT00670852

Intervention type: PROCEDURE
Intervention: X-rays and CT scan
Description: CT Scan x-rays
Study: NCT02049333

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Phacoemulsification

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Phacoemulsification
Study: NCT02899533

Intervention type: DRUG
Intervention: [18F] FES
Description: \[18F\] FES PET/CT scan, imaging tracer
Study: NCT02556697

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bronchoscopy with in vivo confocal endomicroscopy
Description: A bronchoscopy with in vivo confocal endomicroscopy is done for patients with a suspicion of emphysema or for patients with a suspicion of scleroderma

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bronchoscopy with in vivo confocal endomicroscopy
Description: A bronchoscopy with in vivo confocal endomicroscopy is done for patients with a suspicion of emphysema or for patients with a suspicion of scleroderma
Study: NCT01359059

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: Patients in one set (40 patients/set) will receive 150 mg of PGL or placebo at 20:00 the evening before surgery and 1.5 h before surgery and will undergo surgery under GA. The 2nd set of patients will be randomized similarly but will undergo surgery under epidural analgesia. One physician whose duty in the study will end at the point of preoperative preparation will provide the patients with the preemptive drug. No other premedication will be administered to any patient. Post-operatively, patients who received preoperative PGL patients will be given placebo while the pre-surgery-placebo-treated ones will receive PGL, all at 2 h after surgery. All patients will then be given 150 mg twice daily thereafter, Q 12 h postoperatively up to 96 h.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: Patients in one set (40 patients/set) will receive 150 mg of PGL or placebo at 20:00 the evening before surgery and 1.5 h before surgery and will undergo surgery under GA. The 2nd set of patients will be randomized similarly but will undergo surgery under epidural analgesia. One physician whose duty in the study will end at the point of preoperative preparation will provide the patients with the preemptive drug. No other premedication will be administered to any patient. Post-operatively, patients who received preoperative PGL patients will be given placebo while the pre-surgery-placebo-treated ones will receive PGL, all at 2 h after surgery. All patients will then be given 150 mg twice daily thereafter, Q 12 h postoperatively up to 96 h.
Study: NCT05466760

Intervention type: RADIATION
Intervention: PET/MR
Description: Study 1- pre-NAC PET/MR; Study 2- first follow-up PET/MR is performed after first dose of NAC; Study 3, second follow-up PET/MR is performed after third or fourth dose of the NAC. The NAC protocol is mainly antracycline-based followed by taxane-based regimen for a total of 6-8 cycles.
Study: NCT02084576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nepafenac
Description: One drop in the study eye 3 times daily for 30 days
Study: NCT02049333

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Cycloplasty (ECPL)
Study: NCT02084576

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: One drop in the study eye 4 times daily for 30 days
Study: NCT02339194

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Denture fabrication technique
Description: Both arm groups are composed by patients present severely resorbed mandibular alveolar bones who will receive complete dentures fabricated by means of a simpler techinique previously proved to be effective. Although for the traditional protocol group a second more complex impression step will be performed in order to evaluate if the simpler approach for this anatomical condition could be safely applied.
Study: NCT01255995

Intervention type: DEVICE
Intervention: Capsular Tension Ring
Description: Capsular Tension Ring
Study: NCT03088943

Intervention type: OTHER
Group type: OTHER
Intervention: TTE Apical 4 Chamber View
Description: We will measure a number of echocardiography parameters by TTE (apical 4 Chamber View) prior to and after induction

Intervention type: OTHER
Group type: OTHER
Intervention: TEE dTG View
Description: We will measure a number of echocardiography parameters by TEE (dTG View) prior to cardiopulmonary bypass and after cardiopulmonary bypass (atrially paced at 80, 100, and 120 bpm)
Study: NCT04645303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hyaluronic acid (20 mg/2 mL)
Description: A1-Pulley infiltration for trigger finger
Study: NCT03088943

Intervention type: OTHER
Group type: OTHER
Intervention: TEE ME 4C View
Description: We will measure a number of echocardiography parameters by TEE (ME 4C View) prior to cardiopulmonary bypass and after cardiopulmonary bypass (atrially paced at 80, 100, and 120 bpm)
Study: NCT00449644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC207
Description: TMC207 400mg (4 tablets) once daily for 14 days, 200mg (2 tablets) three times a week for 6 or 22 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC207
Description: TMC207 400mg (4 tablets) once daily for 14 days, 200mg (2 tablets) three times a week for 6 or 22 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 4 tablets once daily for 14 days, 2 tablets three times a week for 6 or 22 weeks.
Study: NCT01982461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: 10mg,once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crestor®
Description: 10mg,once daily
Study: NCT03858530

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultrasound Examination
Description: Grayscale ultrasound, Doppler ultrasound, ultrasound elastography with or without ultrasound intravenous contrast will be performed.
Study: NCT00449644

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 4 tablets once daily for 14 days, 2 tablets three times a week for 6 or 22 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Background regimen (BR) for MDR-TB (multi-drug resistant tuberculosis)
Description: Background Regimen (BR) of antibacterial drugs used in the treatment of TB according to national TB program and selected at the baseline visit as speciified in the protocol for up to 96 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Background regimen (BR) for MDR-TB (multi-drug resistant tuberculosis)
Description: Background Regimen (BR) of antibacterial drugs used in the treatment of TB according to national TB program and selected at the baseline visit as speciified in the protocol for up to 96 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Background regimen (BR) for MDR-TB (multi-drug resistant tuberculosis)
Description: Background Regimen (BR) of antibacterial drugs used in the treatment of TB according to national TB program and selected at the baseline visit as speciified in the protocol for up to 96 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Background regimen (BR) for MDR-TB (multi-drug resistant tuberculosis)
Description: Background Regimen (BR) of antibacterial drugs used in the treatment of TB according to national TB program and selected at the baseline visit as speciified in the protocol for up to 96 weeks.
Study: NCT01660854

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Heterologous challenge
Description: challenge by the bites of 5 Plasmodium falciparum infected mosquitoes.
Study: NCT01948063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ubiquinol
Description: Depending on the patient's ability to swallow pills, patients in the experimental group will receive 200mg Ubiquinol in either a pill or a liquid. The liquid form of the study med will be mixed with 50 milliliters of Ensure (a dietary supplement) to ensure blinding. This will be given every 12 hours for 7 days or until hospital discharge.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Depending on the patient's ability to swallow pills, patients in the control group will receive a placebo pill or a liquid placebo, which is 50 milliliters of Ensure (a dietary supplement). This will be given every 12 hours for 7 days or until hospital discharge.
Study: NCT03415438

Intervention type: DIAGNOSTIC_TEST
Intervention: Visual Analogue Scale
Description: intensity of pain perception patients feel

Intervention type: DIAGNOSTIC_TEST
Intervention: Visual Analogue Scale
Description: intensity of pain perception patients feel

Intervention type: DIAGNOSTIC_TEST
Intervention: posterior capsule tightness
Description: tape measurement for posterior capsule tightness with patients lying at side and horizontally adducting their shoulder.

Intervention type: DIAGNOSTIC_TEST
Intervention: posterior capsule tightness
Description: tape measurement for posterior capsule tightness with patients lying at side and horizontally adducting their shoulder.

Intervention type: DIAGNOSTIC_TEST
Intervention: shortness tests for lumbar movements
Description: tape measurement for lumbar movements

Intervention type: DIAGNOSTIC_TEST
Intervention: shortness tests for lumbar movements
Description: tape measurement for lumbar movements

Intervention type: DIAGNOSTIC_TEST
Intervention: range of motion tests for lumbar movements
Description: range of motion measurements for lumbar flexion, extension and lateral flexion with goniometer.

Intervention type: DIAGNOSTIC_TEST
Intervention: range of motion tests for lumbar movements
Description: range of motion measurements for lumbar flexion, extension and lateral flexion with goniometer.

Intervention type: DIAGNOSTIC_TEST
Intervention: The thoracolumbar fascia length test
Description: patient sitting straight with shoulders at horizontal plane, both the arms are asked to rotated with primarily spinal rotation. the degree of rotation gives idea about the thoracolumbar fascia length

Intervention type: DIAGNOSTIC_TEST
Intervention: The thoracolumbar fascia length test
Description: patient sitting straight with shoulders at horizontal plane, both the arms are asked to rotated with primarily spinal rotation. the degree of rotation gives idea about the thoracolumbar fascia length

Intervention type: DIAGNOSTIC_TEST
Intervention: Modify Schober test
Description: tape measurement of spinal flexion between designated regions

Intervention type: DIAGNOSTIC_TEST
Intervention: Modify Schober test
Description: tape measurement of spinal flexion between designated regions
Study: NCT00887510

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide
Description: 25 mg tablet once daily for 6 weeks~Other Names:~HCTZ

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide
Description: 25 mg tablet once daily for 6 weeks~Other Names:~HCTZ

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trandolapril
Description: 4 mg tablet once daily for 6 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trandolapril
Description: 4 mg tablet once daily for 6 weeks